Iker Núñez-Carpintero

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Network Analysis

Radical Prostatectomy

Single Molecule

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Iker Núñez-Carpintero, Maria Rigau, Mattia Bosio, Emily O'Connor, Sally Spendiff, Yoshiteru Azuma, Ana Topf, Rachel Thompson, Peter A C 't Hoen, Teodora Chamova, Ivailo Tournev, Velina Guergueltcheva, Steven Laurie, Sergi Beltran, Salvador Capella, Davide Cirillo, Hanns Lochmüller, Alfonso Valencia
Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes. Nature communications 15 (1) (2024)
Iker Núñez-Carpintero, Maria Rigau, Mattia Bosio, Emily O'Connor, Sally Spendiff, Yoshiteru Azuma, Ana Topf, Rachel Thompson, Peter A C 't Hoen, Teodora Chamova, Ivailo Tournev, Velina Guergueltcheva, Steven Laurie, Sergi Beltran, Salvador Capella, Davide Cirillo, Hanns Lochmüller, Alfonso Valencia
Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes. Nature communications 15 (1) (2024)
Iker Núñez-Carpintero, Maria Rigau, Mattia Bosio, Emily O'Connor, Sally Spendiff, Yoshiteru Azuma, Ana Topf, Rachel Thompson, Peter A C 't Hoen, Teodora Chamova, Ivailo Tournev, Velina Guergueltcheva, Steven Laurie, Sergi Beltran, Salvador Capella, Davide Cirillo, Hanns Lochmüller, Alfonso Valencia
Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes. Nature communications 15 (1) (2024)
Alexandros Armaos, François Serra, Iker Núñez-Carpintero, Ji-Heui Seo, Sylvan C Baca, Stefano Gustincich, Alfonso Valencia, Matthew L Freedman, Davide Cirillo, Claudia Giambartolomei, Gian Gaetano Tartaglia
The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer. Nature communications 14 (1) (2023)